Group One Trading L.P. purchased a new stake in shares of Amedisys Inc (NASDAQ:AMED) in the 4th quarter, HoldingsChannel reports. The fund purchased 771 shares of the health services provider’s stock, valued at approximately $90,000.
Several other hedge funds have also recently added to or reduced their stakes in AMED. Columbus Circle Investors purchased a new position in Amedisys during the 4th quarter worth approximately $5,108,000. Stevens Capital Management LP purchased a new position in Amedisys during the 4th quarter worth approximately $270,000. ClariVest Asset Management LLC raised its position in Amedisys by 45.1% during the 4th quarter. ClariVest Asset Management LLC now owns 100,600 shares of the health services provider’s stock worth $11,782,000 after buying an additional 31,258 shares during the last quarter. Chicago Equity Partners LLC raised its position in Amedisys by 12.1% during the 4th quarter. Chicago Equity Partners LLC now owns 38,460 shares of the health services provider’s stock worth $4,504,000 after buying an additional 4,160 shares during the last quarter. Finally, Financial Gravity Companies Inc. acquired a new stake in shares of Amedisys during the 4th quarter worth approximately $50,000. 96.45% of the stock is owned by institutional investors and hedge funds.
Amedisys stock traded down $0.75 during trading on Wednesday, reaching $134.92. The company had a trading volume of 403 shares, compared to its average volume of 314,414. Amedisys Inc has a 1-year low of $54.29 and a 1-year high of $140.91. The stock has a market capitalization of $4.28 billion, a P/E ratio of 60.77, a P/E/G ratio of 1.72 and a beta of 1.43. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.06 and a current ratio of 1.06.
In other Amedisys news, Director Jake L. Netterville sold 3,394 shares of the firm’s stock in a transaction on Friday, November 16th. The stock was sold at an average price of $122.86, for a total value of $416,986.84. Following the transaction, the director now owns 75,266 shares in the company, valued at approximately $9,247,180.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider David B. Pearce sold 410 shares of the firm’s stock in a transaction on Monday, December 24th. The shares were sold at an average price of $106.61, for a total value of $43,710.10. Following the completion of the transaction, the insider now owns 11,010 shares in the company, valued at approximately $1,173,776.10. The disclosure for this sale can be found here. Insiders sold a total of 7,327 shares of company stock worth $926,346 in the last three months. 2.60% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: This piece was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.com-unik.info/2019/02/13/group-one-trading-l-p-invests-90000-in-amedisys-inc-amed-stock.html.
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.
Recommended Story: What does relative strength index mean?
Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.